No business profile yet.
Size Universal Vision Biotechnology (3218.TWO) is a Taiwan Health Care company (Medical/Nursing Services) with a market value of $309M, the 627th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$122.50 on 18 Nov 2026.
Performance Over six months the shares fell 3.5%, against -4.0% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 4.8% over the last twelve months (peer median +6.0%); the operating margin is 30.8% (peer median 8.0%).
Valuation It trades at 9.2× forward earnings against a peer median of 17.6× (3rd cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -29 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$4.41B | NT$4.20B | NT$4.23B | NT$4.08B | NT$3.49B |
| Revenue growth | — | -1% | +4% | +17% | — |
| Gross profit | NT$2.40B | NT$2.34B | NT$2.37B | NT$2.31B | NT$2.02B |
| EBITDA | NT$1.94B | NT$1.92B | NT$1.92B | NT$1.76B | NT$1.45B |
| Net income | NT$1.07B | NT$1.04B | NT$1.06B | NT$1.05B | NT$851M |
| Free cash flow | NT$1.54B | NT$1.10B | NT$1.24B | NT$1.08B | NT$778M |
| Capital expenditure | NT$458M | NT$564M | NT$437M | NT$474M | NT$493M |
| Total debt | NT$1.36B | NT$1.06B | NT$1.05B | NT$964M | NT$972M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3218.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.5% | -8.8% | 11th highest of 21 |
| 6-month return | -3.5% | -4.0% | 10th highest of 20 |
| Distance from 52-week high | -23.9% | -30.8% | 10th highest of 21 |
| Revenue growth (TTM) | +4.8% | +6.0% | 10th lowest of 21 |
| Operating margin | 30.8% | 8.0% | 2nd highest of 21 |
| Forward P/E | 9.2× | 17.6× | 3rd cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -13.8% | 6.6% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +15.4% | +16.5% | 9th highest of 17 |
| Hurdle (Req g minus delivered) | -29.2 pp | -10.9 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +18.7 pp | -2.5 pp | 2nd highest of 20 |
| EV / EBITDA | 5.4× | 9.8× | 3rd cheapest of 13 |
| Net debt / EBITDA | 0.2× | 1.6× | 6th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 9.2× | -13.8% | +15.4% |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 4.1× | -10.7% | +24.4% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 19.8× | 3.4% | +15.3% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | n/a | 19.6% | +27.5% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | n/a | 5.4% | +21.8% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | n/a | 18.8% | -5.8% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | n/a | -14.9% | +9.6% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 16.4× | -5.3% | +17.9% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 24.6× | 12.3% | -1.5% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |